Abstract
AimSingle-tablet antiretroviral regimens (STRs) are used to simplify ART and improve adherence in individuals living with HIV. In routine care, MTR-to-STR switching may also be driven by adverse effects, toxicity concerns, non-adherence, and comorbidities. We evaluated adherence, virological, immunological, and laboratory outcomes, switching reasons, and subsequent regimen modifications.MethodsThis retrospective single-center study included 53 adults with HIV who switched from MTRs to STRs. We compared demographic characteristics, ART regimens, switching reasons, HIV RNA, CD4+ T-lymphocyte counts, creatinine, lipid parameters, and adherence before and after switching.ResultsMean age was 42.8 ± 13.1 years, and 83% were male. Mean MTR duration was 37.9 ± 26.7 months. Main reasons for switching were simplification (43.4%), neuropsychiatric adverse effects (16.9%), non-adherence (9.4%), and reduced GFR, hyperlipidemia, or osteopenia (5.7% each). Adherence increased from 90.0% to 94.3%. At one year, virological suppression was largely maintained, and CD4+ T-lymphocyte counts remained stable. Median creatinine increased only with TDF/FTC/EVG/c (0.78 to 0.89 mg/dL; P = .008), but not with TAF/FTC/EVG/c or ABC/3TC/DTG. A second regimen change was required in 14 patients (26.4%), mainly due to reduced GFR or neuropsychiatric adverse effects. Re-switch rates differed among STRs (P < .001): 47.6% with TDF/FTC/EVG/c, 30.8% with ABC/3TC/DTG, and 0% with TAF/FTC/EVG/c. ConclusionsMTR-to-STR switching improved adherence and preserved virological suppression over one year. However, approximately one-quarter required another regimen change, mainly for renal or neuropsychiatric concerns. These findings support individualized post-switch follow-up, including renal, neuropsychiatric, and metabolic monitoring.
Keywords
Introduction
Human immunodeficiency virus (HIV) infection remains a major global public health challenge. According to 2024 World Health Organization (WHO) data, approximately 40 million people are living with HIV, and 77% have access to antiretroviral therapy (ART).1 ART has transformed HIV into a manageable chronic condition by enabling durable virological suppression, immune preservation, and prevention of clinical progression, while also reducing transmission and limiting drug resistance.2-4
Current guidelines recommend regimens based mainly on two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI); protease inhibitor-based regimens or two-drug combinations may also be considered in selected cases.5,6 Although early ART initiation is essential, sustained virological and immunological success largely depends on treatment adherence. High pill burden, complex dosing, and adverse effects are associated with reduced adherence.4,5,7,8 Single-tablet regimens (STRs) are fixed-dose combinations that can improve adherence and virological suppression compared with multi-tablet regimens (MTRs).2,7-9 As people living with HIV age, monitoring for comorbidities and long-term ART-related toxicities becomes increasingly important.10,11 In Türkiye, few studies have assessed clinical and laboratory outcomes after MTR-to-STR switching. This study aimed to evaluate the reasons for switching and changes in virological, immunological, biochemical, and adherence outcomes in adults living with HIV followed at our clinic.
Materials and Methods
This single-center retrospective study evaluated clinical and laboratory data from adults living with HIV followed at the Infectious Diseases and Clinical Microbiology Outpatient Clinic of Mersin University Hospital. Patients aged ≥18 years with HIV confirmed by ELISA and Western blot were included if they switched from MTRs to STRs between January 2010 and December 2020, with ≥1 year of post-switch follow-up.
The treatment course was divided into three phases: MTR treatment was defined as first-line therapy, the first STR as second-line therapy, and any subsequent regimen after STR modification as third-line therapy. First-line regimens included tenofovir disoproxil fumarate/emtricitabine plus efavirenz (TDF/FTC + EFV), TDF/FTC plus dolutegravir (DTG), TDF/FTC plus lopinavir/ritonavir (LPV/r), TDF/FTC plus darunavir/ritonavir (DRV/r), TDF/FTC plus raltegravir (RAL), and zidovudine/lamivudine (ZDV/3TC) plus LPV/r. The STRs included TDF/FTC/elvitegravir/cobicistat (EVG/c), tenofovir alafenamide (TAF)/FTC/EVG/c, and abacavir (ABC)/3TC/DTG.
Clinical data, including demographics, transmission route, reason for HIV testing, smoking and alcohol use, comorbidities, co-infections, and treatment-related adverse effects, were obtained from records. HIV RNA levels, CD4+ T-lymphocyte counts, creatinine levels, glomerular filtration rate (GFR), lipid profiles, and bone mineral density were assessed by treatment phase. We defined an undetectable viral load as HIV RNA below the lower assay quantification limit (<40 copies/mL). Neuropsychiatric adverse effects included sleep disturbances, anxiety, depressive symptoms, dizziness, and other central nervous system-related complaints. Treatment adherence was based on clinician assessments and patient self-reports; no standardized adherence scale was used.
Ethical ApprovalThis study received ethical approval from the Mersin University Clinical Research Ethics Committee (Date: May 8, 2019; No. 184).Statistical AnalysisData were analyzed using Jamovi version 2.6 (The Jamovi Project, 2024). Quantitative variables were presented as mean ± SD (median [IQR]), and categorical variables as n (%). Normality was assessed using the Shapiro-Wilk test. Paired comparisons were performed using the Wilcoxon signed-rank test, and categorical variables were compared using Fisher’s exact test. Statistical significance was set at P < .05.
Reporting GuidelinesThis study was reported in accordance with the STROBE statement.
Results
Demographic and Clinical CharacteristicsFifty-three adults living with HIV who switched from MTRs to STRs were included. The mean age was 42.8 ± 13.1 years (range, 23–67), and 83.0% (n = 44) were male. Sexual contact was the transmission route in 75.5% (n = 40), including heterosexual contact in 67.5% (n = 27) and men who have sex with men in 32.5% (n = 13). HIV was most commonly diagnosed during symptom evaluation (47.2%; n=25) or after suspected exposure (26.4%; n=14) (Table 1). Comorbidities and coinfections were present in 34.0% (n = 18) and 41.5% (n = 22), respectively.
The mean baseline viral load was 2.03 × 10⁶ ± 1.10 × 10⁷ copies/mL (median [IQR], 129,247). At the end of the first year of first-line therapy, data were available for 43 patients; mean viral load decreased to 118.3 ± 690 copies/mL (0) and HIV RNA was undetectable in 83.7% (n = 36). Before switching, mean viral load was 3955 ± 16,603 copies/mL (0), and HIV RNA was undetectable in 75.5% (n = 40). Mean CD4+ T-lymphocyte count increased from 375.6 ± 223.7 cells/mm³ (376) at baseline to 667.0 ± 318.0 cells/mm³ (693) at one year and 759.0 ± 375.3 cells/mm³ (794) before switching. One year after switching, the CD4+ T-lymphocyte count was 790 ± 443 cells/mm³ (797). During first-line therapy, HIV RNA decreased, and CD4+ T-lymphocyte counts increased significantly (both P < .001). Serum creatinine (P = .001), total cholesterol (P < .001), and triglyceride levels (P = .041) also increased significantly (Table 2).Treatment RegimensFirst-line MTRs were TDF/FTC + EFV in 47.2% (n = 25), TDF/FTC + DTG in 26.4% (n = 14), TDF/FTC + LPV/r in 18.9% (n = 10), and other regimens in 7.5% (n = 4). Treatment adherence during this period was 90.0% (n = 48). Second-line STRs were TDF/FTC/EVG/c in 39.6% (n = 21), TAF/FTC/EVG/c in 35.8% (n = 19), and ABC/3TC/DTG in 24.5% (n = 13). Treatment adherence increased to 94.3% (n = 50) during STR therapy.
Among 53 patients receiving second-line therapy, 26.4% (n = 14) underwent further regimen changes; eight from TDF/FTC/EVG/c to TAF/FTC/EVG/c, four from ABC/3TC/DTG to TAF/FTC/EVG/c, one from TDF/FTC/EVG/c to ABC/3TC/DTG, and one from TDF/FTC/EVG/c to TDF/FTC + DTG (Table 3). Re-switch rates differed significantly among STRs (P < .001), reaching 47.6% (10/21) with TDF/FTC/EVG/c and 30.8% (4/13) with ABC/3TC/DTG, with no re-switch in the TAF/FTC/EVG/c group (0/19).
Among patients with paired measurements, serum creatinine increased significantly after STR switching only with TDF/FTC/EVG/c (n=21; 0.78 [0.73–0.87] to 0.89 [0.77–1.00] mg/dL; P = .008), but not with TAF/FTC/EVG/c (n=18; 0.83 [0.76–1.02] to 0.84 [0.73–0.91] mg/dL; P = .868) or ABC/3TC/DTG (n=13; 0.99 [0.80–1.12] to 0.96 [0.89–1.06] mg/dL; P = 1.000).Reasons for Switching from First-Line to Second-Line TherapyMean time from first- to second-line therapy was 37.9 ± 26.7 months (1–108). Switching reasons were treatment simplification (43.4%; n=23), neuropsychiatric adverse effects (16.9%; n=9), non-adherence (9.4%; n=5), reduced GFR, prevention of long-term toxicity, hyperlipidemia, or osteopenia (5.7%; n=3 each), lipodystrophy (3.8%; n=2), gastrointestinal adverse effects (1.9%; n = 1), and drug interactions (1.9%; n = 1) (Table 3).
At treatment initiation, 80.4% (n=41/51) had stage 1 and 19.6% (n=10/51) had stage 2 renal function according to CKD-EPI-calculated GFR; no patient had stage ≥3 impairment. By switching, stage 3 renal impairment had developed in three patients (5.7%) (Table 2). Among TDF-based MTRs, creatinine increased significantly with TDF/FTC + DTG (median 0.93 [0.87–1.03] to 1.03 [0.97–1.17] mg/dL; P = .001), although values largely remained normal; two patients switched to ABC/3TC/DTG for GFR decline. No GFR-related switch occurred with EFV + TDF/FTC, whereas one patient receiving TDF/FTC + LPV/r switched to TAF/FTC/EVG/c.
Hyperlipidemia-related switching occurred in two patients receiving TDF/FTC + LPV/r, who switched to TDF/FTC/EVG/c and started lipid-lowering therapy, and in one patient receiving TDF/FTC + RAL, who switched to ABC/3TC/DTG. Lipodystrophy led to switching to TAF/FTC/EVG/c in two patients, one from the LPV/r group and one from the DRV/r group. Osteopenia developed in two patients receiving TDF/FTC + DTG and one receiving EFV + TDF/FTC, leading to switching to TAF/FTC/EVG/c.Reasons for Switching from Second-Line to Third-Line TherapyAt the first-year follow-up after second-line therapy, non-adherence persisted in three patients, two of whom required treatment change; the remaining patients maintained virological suppression. Overall, 26.4% (n = 14) switched to third-line therapy because of reduced GFR (9.4%; n=5), neuropsychiatric adverse effects (7.5%; n=4), non-adherence (3.8%; n=2), prevention of long-term toxicity (3.8%; n=2), and osteopenia (1.9%; n=1) (Table 3). During the first year of STR therapy, no regimen change was made for hyperlipidemia; however, lipid-lowering therapy was initiated in two patients receiving TAF/FTC/EVG/c within six months. Among patients who underwent third-line switching after TDF/FTC/EVG/c, eight switched to TAF/FTC/EVG/c, one to ABC/3TC/DTG and one to TDF/FTC + DTG. Among patients who underwent third-line switching after ABC/3TC/DTG, all four switched to TAF/FTC/EVG/c because of neuropsychiatric adverse effects.
Discussion
With prolonged survival among people living with HIV receiving ART, treatment success is increasingly linked to virological efficacy, adherence, regimen simplicity, and long-term toxicity management.2,10,11 This study evaluated virological, immunological, and metabolic outcomes after MTR-to-STR switching. Switching improved treatment adherence and maintained virological suppression in most patients. Nevertheless, 26.4% of patients required a further regimen change, and re-switch rates differed significantly among STR regimens (P < .001). The highest re-switch rate occurred in the TDF/FTC/EVG/c group, whereas no re-switch was observed in the TAF/FTC/EVG/c group. These findings suggest that STR choice, rather than simplification alone, may influence treatment durability. Sustained adherence is central to long-term ART success. In our study, adherence increased from 90.0% during MTR therapy to 94.3% after STR switching, consistent with previous reports.2,8,12 Altice et al.2 reported that STR use increased the likelihood of optimal adherence by 63%, while Clay et al.12 found that patients receiving STRs were 2.37 times more likely to be adherent than those receiving MTRs. Improved STR adherence may support virological outcomes.2,8,9,12,13 However, evidence for a consistent virological advantage over MTRs remains limited and heterogeneous.2,8,14 In our study, virological suppression was maintained in most patients during the first post-switch year. The increase in mean CD4+ T-lymphocyte counts from 375.6 to 759.0 cells/mm³ during the MTR period, followed by stabilization after switching, suggests that the immunological response was preserved. Costa et al.14 similarly reported no significant difference between regimen groups in immunological recovery. Achieving virological and immunological targets with ART does not ensure long-term regimen suitability. Adverse effects, metabolic or organ toxicities, drug interactions, and tolerability problems may require regimen modification.10,11,15,16 In our study, 45.3% of switches from first-line therapy to an STR were related to adverse effects or toxicity concerns, making this the most common switching reason. Çakır et al.15 also found that drug-related adverse effects were the most frequent reason for ART modification (43%), followed by patient-related factors (25%). With wider STR availability, regimen changes are also used to reduce treatment burden and improve patient comfort.5,16 Treatment simplification accounted for 43.4% of switches, comparable to the simplification rate of 55.4% reported by Loghin et al.17 Among adverse effects leading to treatment modification, hyperlipidemia, neuropsychiatric symptoms, renal toxicity, osteoporosis, and gastrointestinal intolerance have been reported most frequently.15-17 In our study, neuropsychiatric adverse effects were the most common drug-related reason for switching (16.9%) and were predominantly associated with EFV-containing regimens. Eight of 25 patients receiving EFV + TDF/FTC switched because of neuropsychiatric symptoms, such as dizziness, sleep disturbances, and mood changes. This is consistent with Leutscher et al.,18 who attributed most EFV discontinuations to neuropsychiatric disturbances. Fernández-Bargiela et al.19 also showed that neuropsychiatric-related discontinuation was significantly higher in the EFV group than in the DTG group. All four re-switches in the ABC/3TC/DTG group were due to neuropsychiatric symptoms attributed to dolutegravir. Although DTG-related neuropsychiatric adverse effects have been reported infrequently in clinical trials, real-world data suggest higher discontinuation rates.20,21 Hoffmann et al.21 reported that DTG-related neuropsychiatric discontinuation reached 5.6% in real-world cohorts and identified concomitant abacavir use as an independent risk factor. Despite the limited sample size, this clustering was consistent with previous reports on this combination. In this study, reduced GFR prompted regimen changes at both treatment stages. Before STR switching, stage 3 renal impairment developed in three patients receiving TDF-containing MTRs; during STR therapy, five patients receiving TDF/FTC/EVG/c re-switched to TAF/FTC/EVG/c because of reduced GFR. Among STR recipients, serum creatinine increased significantly only with TDF/FTC/EVG/c, with no significant change in the TAF/FTC/EVG/c or ABC/3TC/DTG groups. These findings are consistent with previous reports of TDF-associated renal effects.22,23 In our study, cobicistat was included in both the TDF/FTC/EVG/c and TAF/FTC/EVG/c regimens, but creatinine increased significantly only in the TDF-containing group. This suggests that cobicistat alone is unlikely to explain the increase and that TDF-related toxicity may have contributed. However, tubular biomarkers and proteinuria trajectories were not assessed. These results should be interpreted as a renal safety signal rather than definitive evidence of structural nephrotoxicity. Osteopenia led to regimen changes in three patients during the MTR period and in one patient during the STR period. All affected patients were receiving TDF-containing regimens and switched to TAF- or ABC-based alternatives. This finding is consistent with the literature reporting adverse effects of TDF and prolonged ART exposure on bone mineral density, as well as with previous data from Türkiye.11,15,24 Lipid abnormalities occurred during both MTR and STR periods. Before switching, 60% and 40.7% of patients had elevated triglyceride and total cholesterol levels, respectively. During STR therapy, lipid-lowering treatment was initiated in two patients receiving TAF/FTC/EVG/c, but no regimen change was required for hyperlipidemia. These cases are consistent with real-world data suggesting that lipid profiles may worsen after switching from TDF to TAF, partly because of the loss of TDF's lipid-lowering effect.25-27 In contrast, Loghin et al.17 reported significant reductions in elevated triglyceride and total cholesterol rates in a cohort predominantly switched from PI-based MTRs to INSTI- or NNRTI-based STRs. Thus, metabolic effects may depend on both prior therapy and the components of the new STR. Hyperlipidemia led to regimen change in patients receiving LPV/r-based regimens, in line with the known dyslipidemic effect of these boosted PIs.11,15 Lipid changes after regimen simplification should therefore be interpreted according to both the selected STR and the preceding treatment regimen. After STR switching, 26.4% of patients underwent further regimen changes. Re-switch rates differed significantly among STR regimens (P < .001), reaching 47.6% in the TDF/FTC/EVG/c group and 30.8% in the ABC/3TC/DTG group, whereas no re-switches were observed in the TAF/FTC/EVG/c group. This difference may be explained by the clustering of renal events in TDF-containing STR and neuropsychiatric intolerance in DTG-containing STR. The absence of re-switching in the TAF/FTC/EVG/c group is consistent with Rolle et al.,28 who observed high rates of virological suppression and low discontinuation rates after switching to a TAF-based STR plus boosted darunavir. This finding also aligns with data from the Turkish HIV-TR cohort, in which Korten et al.16 showed that INSTI-based regimens were associated with lower discontinuation rates due to intolerance and toxicity than NNRTI- and PI-based regimens. These results do not prove regimen superiority. Because this was a non-randomized study with small subgroups, regimen selection may have reflected baseline toxicity concerns, physician preference, and drug availability. Thus, one simplification step may not provide durable therapy for every patient. Individualized regimen selection and regular post-switch monitoring may be needed.
Limitations
The retrospective, single-center design and small sample size limited statistical power, particularly in subgroup analyses, and precluded definitive causal inferences. Adherence was based on clinical documentation. Some laboratory parameters, including lipid profiles, were unavailable at all time points.
Conclusion
MTR-to-STR switching improved adherence while largely maintaining virological suppression and immunological recovery. However, 26.4% of patients required a further regimen change, with significant differences among STRs. These changes were mainly associated with TDF-related renal decline and DTG-related neuropsychiatric adverse effects, suggesting that tenofovir formulations and the third agent remain clinically important in ART simplification. Therefore, individualized regimen selection and regular post-switch monitoring of renal, neuropsychiatric, and metabolic parameters should be part of real-world switching strategies. Larger prospective multicenter studies are needed to define optimal ART switching strategies.
Declarations
Animal and Human Rights Statement
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was waived by the Ethics Committee due to the retrospective design and use of anonymized patient data.
Data Availability
The datasets used and/or analyzed during the current study are not publicly available due to patient privacy but are available from the corresponding author upon reasonable request.
Conflict of Interest
The authors declare no conflict of interest.
Funding
None.
Author Contributions (CRediT Taxonomy)
Conceptualization: S.K.G., A.K., G.E.
Methodology: S.K.G., A.K., G.E.
Formal Analysis: S.K.G., H.G.
Investigation: S.K.G., A.K., G.E.
Data Curation: S.K.G., H.G., G.E.
Writing – Original Draft: S.K.G., H.G.
Writing – Review & Editing: S.K.G., A.K., G.E., H.G.
Supervision: A.K.
AI Usage Disclosure
No artificial intelligence (AI) tools were used in the study design, analysis, writing, or generation of scientific content.
Abbreviations
ABC: Abacavir
ART: Antiretroviral therapy
DTG: Dolutegravir
EFV: Efavirenz
ELISA: Enzyme-linked immunosorbent assay
FTC: Emtricitabine
GFR: Glomerular filtration rate
HIV: Human immunodeficiency virus
INSTI: Integrase strand transfer inhibitor
MTR: Multi-tablet regimen
NNRTI: Non-nucleoside reverse transcriptase inhibitor
NRTI: Nucleos(t)ide reverse transcriptase inhibitor
RAL: Raltegravir
STR: Single-tablet regimen
TAF: Tenofovir alafenamide
TDF: Tenofovir disoproxil fumarate
WHO: World Health Organization
ZDV: Zidovudine
References
- World Health Organization. WHO HIV data and statistics, 2024. Accessed April 16, 2026. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics.
- Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: a systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475-490. doi:10.2147/ppa.s192735
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. doi:10.1056/nejmoa1105243
- Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. Fed Pract. 2016;33(suppl 3):24S-30S.
- Ambrosioni J, Levi L, Alagaratnam J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24(11):1126-1136. doi:10.1111/hiv.13542
- World Health Organization. WHO Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Published July 16, 2021. Accessed April 16, 2026. https://www.who.int/publications/i/item/9789240031593.
- Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single- and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17. doi:10.1186/s12981-018-0204-0
- Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297-1307. doi:10.1093/cid/ciu046
- Kapadia SN, Grant RR, German SB, et al. HIV virologic response better with single-tablet once-daily regimens compared to multiple-tablet daily regimens. SAGE Open Med. 2018;6:2050312118816919. doi:10.1177/2050312118816919
- Balli Turhan FN, Kara E, İnkaya AÇ, Demirkan K, Ünal S. HIV ile yaşayan bireylerde ilaç yükü ve ilaç yükünün azaltılması. FLORA. 2024;29(3):313-324. doi:10.5578/flora.2024031124
- Maggi P, De Socio GV, Menzaghi B, et al. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? BMC Infect Dis. 2022;22(1):745. doi:10.1186/s12879-022-07739-y
- Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single- and multi-tablet fixed-dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42). doi:10.1097/md.0000000000001677
- Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(5):587-596. doi:10.1097/qai.0000000000000082
- Costa JDO, Ceccato MDGB, Silveira MR, Bonolo PDF, Reis EA, Acurcio FDA. Effectiveness of antiretroviral therapy in the single-tablet regimen era. Rev Saude Publica. 2018;52:87. doi:10.11606/s1518-8787.2018052000399
- Çakır Y, İnce N, Çalışkan E, Tunca B, Yekenkurul D. Evaluation of factors affecting antiretroviral treatment changes in HIV-positive patients in a university hospital. FLORA. 2023;28(1):117-124. doi:10.5578/flora.20239617
- Korten V, Eren G, Yıldırmak T, et al. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017. AIDS Res Ther. 2021;18(1):4. doi:10.1186/s12981-020-00328-6
- Loghin II, Rusu Șerban A, Vâţă A, et al. Antiretroviral therapy switch in HIV-infected adults from a regional HIV/AIDS center in NE Romania. Medicina (Kaunas). 2024;60(6):854. doi:10.3390/medicina60060854
- Leutscher PDC, Stecher C, Storgaard M, Larsen CS. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013;45(8):645-651. doi:10.3109/00365548.2013.773067
- Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, et al. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022;29(4):207-211. doi:10.1136/ejhpharm-2020-002374
- Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4-10. doi:10.24875/aidsrev.19000023
- Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56-63. doi:10.1111/hiv.12468
- Ibrahim F, Campbell L, Bailey A, et al. Estimated glomerular filtration rate slopes on tenofovir alafenamide. HIV Med. 2020;21(9):607-612. doi:10.1111/hiv.12899
- Surial B, Ledergerber B, Calmy A, et al. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. J Infect Dis. 2020;222(4):637-645. doi:10.1093/infdis/jiaa125
- Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825-831. doi:10.1097/qad.0b013e32835192ae
- Brunet L, Mallon P, Fusco JS, et al. Switch from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: lipid changes and statin underutilization. Clin Drug Investig. 2021;41(11):955-965. doi:10.1007/s40261-021-01081-y
- Lacey A, Savinelli S, Barco EA, et al. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34(8):1161-1170. doi:10.1097/qad.0000000000002541
- Mallon PWG, Brunet L, Fusco JS, et al. Lipid changes after switch from TDF to TAF in the OPERA Cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9(1). doi:10.1093/ofid/ofab621
- Rolle CP, Nguyen V, Hinestrosa F, DeJesus E. Clinical outcomes of HIV-1-infected patients switched from complex multi-tablet regimens to tenofovir alafenamide-based single-tablet regimens plus a boosted protease inhibitor in a real-world setting. J Virus Erad. 2020;6(4):100021. doi:10.1016/j.jve.2020.100021
Tables
Table 1. Demographic and Clinical Characteristics of the Patients
Table 2. Changes in Virological and Biochemical Parameters During First-Line Therapy
Table 3. Treatment Regimens and Reasons for Switching
Additional Information
Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.
Rights and Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
About This Article
How to Cite This Article
Sibel Kuyugöz Gülbudak, Güliz Evik, Harun Gülbudak, Ali Kaya. Clinical and laboratory outcomes after switching to single-tablet antiretroviral regimens in adults with HIV: a single-center retrospective study. Ann Clin Anal Med 2026;18(3):00-00. doi:10.4328/ACAM.50238
Publication History
- Received:
- 13.06.2026
- Accepted:
- 06.09.2026
- Published Online:
- 06.09.2026